Document Detail


Regular coffee but not espresso drinking is protective against fibrosis in a cohort mainly composed of morbidly obese European women with NAFLD undergoing bariatric surgery.
MedLine Citation:
PMID:  22820478     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND & AIMS: The aim of this study was to determine the influence of coffee and other caffeinated drinks on liver fibrosis of severely obese European patients.
METHODS: A specific questionnaire exploring various types of coffee (regular filtrated coffee and espresso), caffeinated drinks, and chocolate was filled in by 195 severely obese patients. All patients had liver biopsies that were analyzed according to the NASH Clinical Research Network Scoring System. Univariate and multivariate analyses of significant fibrosis were performed.
RESULTS: Caffeine came mainly from coffee-containing beverages (77.5%). Regular coffee and espresso were consumed in 30.8% and 50.2% of the patients, respectively. Regular coffee, espresso, and total caffeine consumption was similar between patients with and without NASH. While consumption of espresso, caffeinated soft drinks, and chocolate was similar among patients, with respect to the level of fibrosis, regular coffee consumption was lower in patients with significant fibrosis (F ≥2). According to logistic regression analysis, consumption of regular coffee was an independent protective factor for fibrosis (OR: 0.752 [0.578-0.980], p=0.035) in a model including level of AST (OR: 1.04 [1.004-1.076], p=0.029), presence of NASH (OR: 2.41 [1.007-5.782], p=0.048), presence of the metabolic syndrome (NS), and level of HOMA-IR (NS). Espresso, but not regular coffee consumption was higher in patients with lower HDL cholesterol level, higher triglyceride level, and the metabolic syndrome.
CONCLUSIONS: Consumption of regular coffee but not espresso is an independent protective factor for liver fibrosis in severely obese European patients.
Authors:
Rodolphe Anty; Sophie Marjoux; Antonio Iannelli; Stéphanie Patouraux; Anne-Sophie Schneck; Stéphanie Bonnafous; Camille Gire; Anca Amzolini; Imed Ben-Amor; Marie-Christine Saint-Paul; Eugenia Mariné-Barjoan; Alexandre Pariente; Jean Gugenheim; Philippe Gual; Albert Tran
Related Documents :
21704338 - Familial normal pressure hydrocephalus (nph) with an autosomal-dominant inheritance: a ...
22782968 - Relationship of serum sodium concentration to mortality in a wide spectrum of heart fai...
2044638 - Lovastatin and gemfibrozil in the treatment of type 2a and type 2b hyperlipoproteinemia.
21811698 - Heart rate variability in men with erectile dysfunction.
24668538 - Pulmonary manifestations of polymyositis/dermatomyositis.
20130888 - Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic he...
Publication Detail:
Type:  Comparative Study; Journal Article; Research Support, Non-U.S. Gov't     Date:  2012-07-20
Journal Detail:
Title:  Journal of hepatology     Volume:  57     ISSN:  1600-0641     ISO Abbreviation:  J. Hepatol.     Publication Date:  2012 Nov 
Date Detail:
Created Date:  2012-10-19     Completed Date:  2013-07-01     Revised Date:  2013-07-03    
Medline Journal Info:
Nlm Unique ID:  8503886     Medline TA:  J Hepatol     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  1090-6     Citation Subset:  IM    
Copyright Information:
Copyright © 2012 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
Affiliation:
Institut National de Santé et de Recherche Médicale (INSERM), U1065, Team 8, Hepatic Complications in Obesity, Nice, F-06204 Cedex 3, France. rodolphe.anty@laposte.net
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Bariatric Surgery*
Biopsy
Cacao
Caffeine
Coffee / classification*
Cohort Studies
Cola
Comorbidity
Europe / epidemiology
Fatty Liver / epidemiology*,  pathology
Female
Humans
Liver / pathology
Liver Cirrhosis / prevention & control*
Male
Middle Aged
Obesity, Morbid / epidemiology*,  surgery*
Questionnaires
Tea
Chemical
Reg. No./Substance:
0/Coffee; 0/Tea; 58-08-2/Caffeine
Comments/Corrections
Comment In:
J Hepatol. 2013 Jun;58(6):1264-5   [PMID:  23376892 ]
J Hepatol. 2013 Jun;58(6):1265-6   [PMID:  23376891 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Intraocular pressure and central corneal thickness in the COMET cohort.
Next Document:  Adenoviral Dominant Negative Soluble Pdgfr? Improves Hepatic Collagen, Systemic Hemodynamics and Por...